242 related articles for article (PubMed ID: 26652963)
1. [Hypolipidemic and antihypertensive therapy in diabetic patients in the Czech Republic: notes on the VZP (General Health Insurance Company) Data].
Šnejdrlová M; Češka R; Janíčková-Žďárská D; Honěk P; Dušek P; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S30-7. PubMed ID: 26652963
[TBL] [Abstract][Full Text] [Related]
2. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
3. Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic.
Chmelík Z; Vaclová M; Lánská V; Laštůvka J; Vrablík M
Cent Eur J Public Health; 2020 Jun; 28(2):114-119. PubMed ID: 32592555
[TBL] [Abstract][Full Text] [Related]
4. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
6. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
Vrablík M; Chmelík Z; Lánská V
Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives of the pharmacological management of diabetic dyslipidemia.
Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
10. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS.
Parhofer KG
Rev Invest Clin; 2018; 70(5):237-243. PubMed ID: 30307445
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Anabtawi A; Moriarty PM; Miles JM
Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
13. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
14. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Lee VW; Ho IC; Chan WS; Tam KY; Lee KK
Am J Cardiovasc Drugs; 2008; 8(3):199-205. PubMed ID: 18533740
[TBL] [Abstract][Full Text] [Related]
15. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
16. Drug therapy of diabetic dyslipidemia: do the statins suffice?
Mooradian AD
Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
[No Abstract] [Full Text] [Related]
17. Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea.
Han KT; Kim S
BMC Cancer; 2022 Feb; 22(1):156. PubMed ID: 35135497
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
Wanner C; Krane V
Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
[TBL] [Abstract][Full Text] [Related]
19. Role for combination therapy in diabetic dyslipidemia.
Warraich HJ; Wong ND; Rana JS
Curr Cardiol Rep; 2015 May; 17(5):32. PubMed ID: 25894802
[TBL] [Abstract][Full Text] [Related]
20. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Pérez A
Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
